Is there another name for retatrutide?
Yes: papers give retatrutide's development code as LY3437943.
GLP-1 / GIP / glucagon triple agonistUpdated
Short answer
Yes: papers give retatrutide's development code as LY3437943.[1]
Other names you will see
Some papers abbreviate it as RETA alongside the LY3437943 code.[2]
An early paper described LY3437943 as a single peptide acting at glucagon, GIP and GLP-1 receptors.[3]
Reviews use descriptive names such as a first-in-class, unimolecular triple hormone receptor agonist.[4]
A seller quoted in an FDA warning letter marketed it as a "glp3 peptide", a commercial label rather than an established drug class name.[5]
More questions on Retatrutide
More on Retatrutide
Sources
- 1Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
- 2Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.npj metabolic health and disease · 2025PMID 40094000Accessed 29 Oct 2026
- 3LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 4Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review.Cardiology in review · 2026PMID 42108533Accessed 2 Oct 2026
- 5Official web pageOfficial web page · web page
Found an error? Report a correction.